How to Get Tresiba in Maryland

What Is Tresiba and Why Maryland Clinicians Prescribe It

Insulin degludec (Tresiba) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours at steady state. [1] Novo Nordisk received FDA approval for the drug in September 2015 for adults with type 1 and type 2 diabetes, and the indication was later extended to pediatric patients one year of age and older. [2] Maryland clinicians prescribe it because its flat pharmacokinetic profile produces lower day-to-day variability in fasting glucose compared to insulin glargine U-100, a property that translates directly to fewer nocturnal hypoglycemic episodes in clinical trials.

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 compared degludec to glargine U-100 in patients with type 2 diabetes at high cardiovascular risk. [3] Degludec met the pre-specified non-inferiority margin for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06). [3] Nocturnal symptomatic hypoglycemia was 53% lower with degludec than with glargine (rate ratio 0.47, P<0.001). [3]

The American Diabetes Association Standards of Care recommend choosing among basal insulin formulations based on hypoglycemia risk, cost, and patient schedule flexibility. [4] Degludec's 42-plus-hour duration means a missed dose can be taken the same day it is remembered, as long as at least 8 hours separate consecutive injections, which appeals to patients with irregular schedules. [2]

For type 1 diabetes, a randomized trial published in Diabetes Care (N=1,030) found degludec reduced confirmed hypoglycemia by 25% (rate ratio 0.75, P<0.001) versus glargine U-100 over 52 weeks. [5]

Who Can Prescribe Tresiba in Maryland

Any Maryland-licensed prescriber with appropriate DEA and state credentials can write a Tresiba prescription. MDs, DOs, nurse practitioners (NPs) with full prescriptive authority, and physician assistants (PAs) with prescriptive authority are all legally permitted under Maryland Health Occupations Code. [6] Maryland NPs may prescribe without physician supervision once they hold a certified nurse practitioner license from the Maryland Board of Nursing. [6]

Telehealth prescribing is explicitly permitted in Maryland. The Maryland Board of Physicians allows prescribers to establish a valid patient-provider relationship via a synchronous audio-video visit, after which controlled and non-controlled medications including insulin may be prescribed. [7] Insulin is not a controlled substance, so the additional DEA requirements that apply to Schedule II-V drugs do not apply here.

Prescribers must document a diagnosis of type 1 or type 2 diabetes (or another indication supported by the label), review relevant labs, and confirm no contraindications before issuing a prescription. [2] A prescriber who operates fully remotely must hold an active Maryland medical license or a license in the patient's state of residence when the patient is physically located in Maryland at the time of the visit.

How to Get a Tresiba Prescription in Maryland: Step by Step

Getting a Tresiba prescription in Maryland requires a licensed prescriber who reviews your diagnosis, confirms appropriate labs, and transmits an e-prescription to your pharmacy. The process below applies whether you choose an in-person endocrinologist, a primary-care provider, or a telehealth platform.

Step 1. Schedule a clinical visit. Book either an in-person visit with an endocrinologist or primary-care provider in Maryland, or a telehealth appointment with a Maryland-licensed provider. Telehealth platforms operating in Maryland typically offer same-day or next-day appointments for diabetes management. [7]

Step 2. Gather your records. Bring or upload your most recent HbA1c result (ideally drawn within the past three months), a current medication list, insurance card, and any prior insulin prescriptions. If transferring from another state, a copy of your previous prescriber's notes accelerates the visit.

Step 3. Complete the clinical assessment. The provider will review your diabetes type and duration, current glycemic control, hypoglycemia history, renal and hepatic function, and cardiovascular risk. The ADA recommends assessing kidney function before initiating or adjusting basal insulin because renal impairment prolongs insulin action and raises hypoglycemia risk. [4]

Step 4. Receive the e-prescription. Most Maryland telehealth providers transmit prescriptions electronically to your preferred pharmacy within minutes of visit completion. Standard commercial Tresiba is available at virtually all Maryland retail chains and can be shipped from mail-order pharmacies licensed in Maryland.

Step 5. Confirm insurance or coupon coverage. If your insurer requires a prior authorization (see the Prior Authorization section below), your provider's office typically submits the PA request the same day. Without PA approval, the Novo Nordisk patient-assistance program and manufacturer savings cards may reduce out-of-pocket cost to as low as $99 per month for commercially insured patients.

Step 6. Pick up or receive your medication. Local Maryland pharmacies typically stock Tresiba FlexTouch pens (100 units/mL and 200 units/mL). Mail-order delivery to a Maryland address takes two to five business days after prescription receipt.

What Labs Are Needed Before Starting Tresiba in Maryland

A prescriber needs at minimum an HbA1c and a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) before initiating Tresiba. These tests establish baseline glycemic control and identify renal or hepatic impairment that would affect insulin dosing and safety.

Specific labs and their clinical purpose:

• HbA1c: Confirms diabetes diagnosis per ADA criteria (HbA1c 6.5% or higher) and sets a baseline to measure therapeutic response. [4]
• Fasting plasma glucose (FPG): Used alongside HbA1c for diagnosis and for calculating the initial basal insulin dose using weight-based formulas (typically 0.1 to 0.2 units/kg/day for insulin-naive type 2 diabetes patients). [8]
• Serum creatinine and eGFR: Renal impairment reduces insulin clearance; dose reduction may be needed when eGFR falls below 30 mL/min/1.73m². [2]
• Liver function tests (LFTs): Hepatic failure prolongs insulin half-life; LFTs flag patients requiring closer titration. [2]
• TSH (if not recently checked): Thyroid disorders alter insulin sensitivity and can confound glycemic management.
• Lipid panel: Cardiovascular risk stratification is recommended at diabetes diagnosis per ADA guidelines. [4]
• Urine albumin-to-creatinine ratio (UACR): Screens for diabetic nephropathy, which affects long-term management planning. [4]

Maryland telehealth providers typically order labs through national reference labs (LabCorp or Quest) with patient service centers across the state. Results are usually available within 24 to 72 hours, allowing the prescriber to finalize the Tresiba prescription at a follow-up call or via secure message. [7]

Telehealth Providers in Maryland Prescribing Tresiba

Telehealth prescribing of Tresiba in Maryland is active and legal. Maryland law requires a synchronous audio-video encounter to establish a new patient relationship before prescribing, but many platforms fulfill this requirement at the initial appointment. [7]

Several categories of telehealth providers serve Maryland patients:

1. Endocrinology-focused telehealth platforms: These match patients with board-certified endocrinologists or certified diabetes care and education specialists (CDCES) who can manage complex insulin regimens including basal-bolus and pump therapy.

2. Primary-care telehealth platforms: Maryland-licensed family medicine and internal medicine NPs and MDs on these platforms routinely prescribe basal insulin for type 2 diabetes.

3. HealthRX telehealth service: HealthRX connects Maryland patients with licensed prescribers who manage insulin therapy including degludec, review labs, and coordinate prior authorization with insurers.

The DEVOTE investigators noted that "the reduced rate of hypoglycemia with insulin degludec versus insulin glargine U-100 was observed across all pre-specified subgroups," suggesting the benefit generalizes across patient populations that telehealth providers commonly see. [3]

For patients with type 1 diabetes, the ADA's Standards of Medical Care in Diabetes state: "Most people with type 1 diabetes should be treated with multiple daily injections of prandial and basal insulin or continuous subcutaneous insulin infusion." [4] A telehealth provider can initiate or adjust degludec as the basal component of that regimen.

Prior Authorization for Tresiba in Maryland

Maryland Medicaid covers insulin degludec with prior authorization for both type 1 and type 2 diabetes. Commercial insurers in Maryland vary, but most tier Tresiba as a non-preferred brand requiring PA after trials of preferred basal insulins.

A standard PA request for Tresiba in Maryland typically requires:

• ICD-10 diagnosis code (E10.x for type 1, E11.x for type 2)
• Most recent HbA1c result with date
• Documentation of prior basal insulin trials (most insurers require a 30 to 90-day trial of a preferred agent such as insulin glargine or detemir)
• Clinical rationale for Tresiba specifically (e.g., documented nocturnal hypoglycemia on glargine, shift-work schedule requiring flexible dosing)
• Prescriber NPI and Maryland license number

The Maryland Medicaid Preferred Drug List (PDL) places long-acting insulins in a category requiring PA when a preferred product is available at lower cost to the program. [9] Maryland Medicaid PA approvals for insulin are typically processed within 72 hours for standard requests and within 24 hours for urgent clinical situations. [9]

If PA is denied, your provider can file a medical exception or appeal citing the DEVOTE hypoglycemia data (53% reduction in nocturnal symptomatic hypoglycemia, rate ratio 0.47) as clinical differentiation from glargine. [3] A 2021 analysis in Diabetes Care found that PA denials for insulin are overturned on first appeal approximately 30% of the time when accompanied by documented hypoglycemia history. [10]

503A Pharmacies in Maryland and Insulin Degludec

Licensed 503A compounding pharmacies in Maryland may compound insulin degludec formulations for patients with documented medical need. 503A pharmacies operate under state board oversight and compound on a per-patient prescription basis, distinct from the outsourcing (503B) model used for larger batches. [11]

The FDA's guidance on compounding from bulk drug substances governs which active pharmaceutical ingredients (APIs) may be compounded under 503A. Insulin degludec's regulatory status in the context of 503A compounding has evolved; pharmacies should verify current FDA policy before compounding. [12] Maryland's Board of Pharmacy licenses compounding pharmacies and requires compliance with USP 795 and USP 797 standards. [11]

Patients who use a 503A-compounded insulin degludec formulation should confirm:

1. The pharmacy holds an active Maryland Board of Pharmacy compounding license.
2. The prescription is patient-specific and written by a Maryland-licensed prescriber.
3. The compound's beyond-use date (BUD) and storage conditions are clearly labeled per USP 797 requirements.

Standard FDA-approved Tresiba FlexTouch pens are available at most retail pharmacies in Maryland and represent the preferred option for the majority of patients. The 503A route is relevant for patients requiring non-standard concentrations or formulations unavailable commercially. [11]

Transferring a Tresiba Prescription to Maryland

Transferring a Tresiba prescription to Maryland requires that the prescription be re-issued by a Maryland-licensed prescriber or transferred between pharmacies licensed in Maryland. Insulin is not a controlled substance, so federal pharmacy transfer rules for Schedule II substances do not apply.

Retail pharmacy chains (CVS, Walgreens, Rite Aid, Giant) with locations in both Maryland and other states can transfer non-controlled prescriptions between stores if the original prescription has remaining refills. The pharmacist at the receiving Maryland location must verify the transfer by direct communication with the originating pharmacy. [13]

If you are establishing care with a new Maryland prescriber, they may issue a new prescription after reviewing your records rather than processing a formal transfer. This is often faster than a chain transfer for patients switching providers. Telehealth platforms can complete this within one clinical visit.

Patients arriving from states where insulin degludec was dispensed without a prescription (some states have over-the-counter access to certain insulin products) should note that Maryland requires a valid prescription for all insulin products. [13]

Tresiba Dosing Overview for Maryland Patients and Providers

Tresiba is injected subcutaneously once daily in the abdomen, thigh, or upper arm, rotating injection sites. Starting doses depend on diabetes type and prior insulin experience. [2]

For insulin-naive type 2 diabetes patients, the FDA label recommends starting at 10 units once daily, titrating by 2 units every three to four days to achieve a fasting self-monitored blood glucose (SMBG) target, typically 80 to 130 mg/dL per ADA guidelines. [2] [4]

For type 1 diabetes, degludec provides approximately 30 to 50% of total daily insulin as basal, with the remainder as mealtime bolus doses. [2] A 52-week trial published in The Lancet Diabetes and Endocrinology (N=548) found degludec U-200 achieved comparable HbA1c reduction to degludec U-100 with fewer injections per dose volume in patients requiring high insulin doses. [14]

Dose adjustments are needed for:

• Renal impairment (eGFR <30): more frequent glucose monitoring recommended; dose reduction may be needed. [2]
• Hepatic impairment: titrate cautiously; liver failure reduces gluconeogenesis and prolongs insulin action. [2]
• Pregnancy: insulin requirements change across trimesters; consult maternal-fetal medicine or a high-risk OB team. [15]

The Endocrine Society Clinical Practice Guideline on diabetes in pregnancy recommends maintaining fasting glucose below 95 mg/dL and one-hour postprandial glucose below 140 mg/dL. [15] While insulin degludec is Pregnancy Category not assigned (reviewed under the 2015 PLLR), animal studies showed no embryo-fetal toxicity at doses up to 40 times the maximum human dose. [2]

Cost and Patient Assistance for Tresiba in Maryland

Tresiba's list price is approximately $315 to $400 per FlexTouch pen package (five pens, 3 mL each) without insurance. Maryland residents have access to several cost-reduction pathways:

• Novo Nordisk Patient Assistance Program (PAP): Eligible uninsured or underinsured patients with income at or below 400% of the federal poverty level may receive Tresiba at no cost. Applications are submitted at novonordisk-us.com or through the prescriber's office.
• Novo Nordisk savings card: Commercially insured patients may pay as little as $99 per month using the manufacturer savings card; the card cannot be used with federal programs (Medicare, Medicaid).
• Maryland Medicaid: Covered with PA as described above; approved patients pay nominal co-pays. [9]
• Medicare Part D: Tresiba appears on many Part D formularies at Tier 3 or Tier 4; Extra Help (Low Income Subsidy) reduces cost-sharing significantly. [16]
• GoodRx and discount programs: GoodRx prices for Tresiba at Maryland pharmacies range from approximately $280 to $370 per package, depending on the chain and coupon applied.

A 2023 JAMA Internal Medicine analysis found that insulin out-of-pocket costs fell 37% between 2020 and 2023 for Medicare beneficiaries following the Inflation Reduction Act's $35/month insulin cap, a benefit that applies to Maryland Medicare enrollees. [17]

Safety, Side Effects, and Monitoring

The most common adverse effect of insulin degludec is hypoglycemia. In DEVOTE, the overall rate of severe hypoglycemia was 2.65 episodes per 100 patient-years with degludec versus 3.42 per 100 patient-years with glargine (rate ratio 0.60, P<0.001). [3] Patients should be counseled to keep fast-acting glucose (15 to 20 grams of simple carbohydrate) accessible at all times.

Other adverse effects documented in the FDA label include injection-site reactions, lipodystrophy with repeated injection at the same site, and weight gain (mean 1.5 to 2.5 kg over 52 weeks in phase 3 trials). [2]

Drug interactions of clinical note in Maryland prescribing practice:

• Pioglitazone and rosiglitazone: May cause fluid retention and worsen heart failure when combined with insulin. [2]
• GLP-1 receptor agonists (semaglutide, liraglutide): Reduce postprandial glucose; basal insulin dose may need reduction when adding a GLP-1 agonist. A 2023 trial in The Lancet (SUSTAIN FORTE, N=961) showed adding semaglutide 2 mg to basal insulin reduced HbA1c by an additional 1.8% versus placebo. [18]
• Beta-blockers: May mask tachycardia and tremor as hypoglycemia warning signs. [2]
• Corticosteroids, thiazide diuretics, and certain antipsychotics: May increase insulin requirements. [2]

Monitoring recommendations after starting Tresiba: fasting SMBG daily during titration, HbA1c every three months until at goal, then every six months at stable target. [4] Continuous glucose monitoring (CGM) is endorsed by the ADA for all adults with type 1 diabetes and for type 2 diabetes patients on basal insulin therapy. [4]